Press release

What the funding is for

The funds allow Dolinnov to take its lead drug candidate into toxicology studies. These studies assess the safety of a candidate before it can be tested in humans, and are an essential step of preclinical development. They are designed to reduce the risk of the programme ahead of its next stages.

What Dolinnov does

Dolinnov develops non-opioid treatments for chronic pain. Its approach targets FXYD2, a regulator of the sodium-potassium pump found in the sensory neurons that carry pain signals. Instead of blocking an ion channel, as most non-opioid programmes do, Dolinnov modulates the pump that controls how excitable these neurons are. The company calls this new class of drugs Precision Pump Modulators. Its lead candidate is an antisense oligonucleotide (ASO) designed to reduce FXYD2 in pain-sensing neurons and provide long-lasting relief.

The goal remains the same: to bring a new therapy to the millions of people who live with chronic pain every day.

Thank you

Dolinnov thanks all its investors for their trust, as well as the academic and clinical experts who have shared their knowledge with the team, in particular Dr Céline Greco, Prof. Nadine Attal and Dr Alain Toledano. Thanks also to the mentors, advisors and organisations that have supported the project from the start: Inserm Transfert, SATT AxLR, Bpifrance, the BIC de Montpellier and Neighborhood, the healthtech innovation programme by VCLS.

About Dolinnov

Dolinnov is a preclinical-stage biotech company founded in October 2024 in Montpellier, France, by Grégoire Serra, Stéphanie Ventéo and Jean-Philippe Annereau. It develops Precision Pump Modulators, a new class of non-opioid treatments for chronic pain, starting with an antisense oligonucleotide targeting FXYD2 in pain-sensing neurons.